The preclinical combination of PI3Kγ inhibition and ICI showed promising outcomes: co-administration of PI3Kγ inhibitor with either anti-PD1 or anti-CTLA-4 significantly inhibits 4T1 tumor growth compared with ICI treatment alone (De Henau et al., 2016). This evidence concerns the gene CTLA4 and neoplasm.